Backed VC (Netherlands)

Bain Capital Life Sciences is the dedicated life sciences investment vehicle of Bain Capital, the global investment firm founded in 1984, launched in 2016 under the leadership of Managing Director Adam Koppel and his team. The fund focuses on late clinical and commercial-stage biopharmaceutical, biotechnology, and medical technology companies, typically investing at Series A, B, and growth stages with initial checks from $10 million to $50 million. Bain Capital Life Sciences brings the operational and analytical rigor that characterizes Bain Capital's broader investment platform to the specialized domain of drug development and regulatory approval, helping portfolio companies navigate clinical trial design, regulatory strategy, and commercial preparation. The firm's investment approach emphasizes scientific differentiation, validated mechanisms of action, and clear paths to regulatory approval as primary criteria, alongside the financial discipline and growth optimization methodologies that define Bain Capital's institutional investment culture. Portfolio outcomes have been exceptional. Karuna Therapeutics, a company developing muscarinic activators for psychiatric disorders, was acquired by Bristol-Myers Squibb for approximately $14 billion in 2024, one of the largest biotech acquisitions of the year. Blueprint Medicines, a precision oncology company, is publicly traded on Nasdaq. Dice Therapeutics, which developed oral peptide therapeutics for inflammatory diseases, was acquired by Eli Lilly for $2.4 billion in 2023. Imago BioSciences was acquired by Bristol-Myers Squibb for $1.35 billion in 2022. Beyond its original investments in Arcus, Blueprint, Imago, and Karuna, the portfolio includes additional clinical-stage biopharmaceutical companies.